艾迪药业(688488.SH)：注射用ADB116获得药物临床试验批准通知书

Core Viewpoint - The company, Aidi Pharmaceutical (688488.SH), has received approval from the National Medical Products Administration for clinical trials of its new drug, ADB116, aimed at treating acute ischemic stroke patients [1] Group 1 - The company and its subsidiary, Nanjing Nanda Pharmaceutical Co., Ltd., have been granted a Clinical Trial Approval Notice for the investigational drug [1] - ADB116 is classified as a type 2 chemically modified new drug [1] - The indication for ADB116 is for thrombolytic therapy in patients with acute ischemic stroke [1]